Skip to main content
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.

1P-ETH-LAD

1P-ETH-LAD molecule structure1P-ETH-LAD molecule structure
1-Propionyl-6-ethyl-6-nor-lysergic acid diethylamide
Psychoactive Class
Psychedelic
Chemical Class
Lysergamide

1P-ETH-LAD is a semisynthetic psychedelic of the lysergamide class and a suspected prodrug of ETH-LADcitation needed, structurally related to both LSD and 1P-LSD. Developed as a designer drug, it is reported to be moderately to significantly more potent than LSD. Its effects are often described as more visual and synaesthetic, with a deeper, less emotionally-charged headspace. It remains largely unresearched and is classified as a research chemical.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~25 μg
Light25-60 μg
Moderate60-100 μg
Strong100-200 μg
Heavy200+ μg

Duration

Onset20-60 minutes
Come Up45-90 minutes
Peak3-6 hours
Offset2-4 hours
After Effects8-48 hours
Total8-13 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Physical

Bodily control enhancementNauseaPupil dilationSpontaneous tactile sensationsStimulationTactile enhancement

Cognitive

Analysis enhancementConceptual thinkingDelusionsDéjà vuEmotion enhancementFeelings of interdependent oppositesImmersion enhancementMemory suppressionEgo deathMultiple thought streamsNovelty enhancementPersonal bias suppressionThought accelerationThought loopsTime distortionUnity and interconnectednessWakefulness

Visual

Distortions

Enhancements

Hallucinatory States

1P-ETH-LAD is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics. These effects include:

Transformations

Auditory

EnhancementsDistortionsHallucinations
Adapted from the ETH-LAD subjective effects documentation. 1P-ETH-LAD is a suspected prodrug of ETH-LAD and is reported to produce an effectively identical experience. Forked from Subjective Effect Documentation work byJosie Kins August 2016.

See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)

Pharmacology

Pharmacodynamics

Direct receptor pharmacology of intact 1P-ETH-LAD has not been measured; the located 1P-ETH-LAD study was an analytical and serum-incubation study rather than a receptor assay.citation needed Formation of ETH-LAD in human serum supports a possible prodrug mechanism, consistent with findings reported for other 1-acyl-substituted LSD derivatives, but it does not establish that ETH-LAD alone mediates the effects of 1P-ETH-LAD in humans.1

Pharmacokinetics

In an in-vitro experiment, 1P-ETH-LAD was incubated in human serum at 37 °C and sampled hourly from 0 to 6 hours, with an additional sample at 24 hours. ETH-LAD was detectable at the first one-hour sampling point, while parent 1P-ETH-LAD remained detectable at 24 hours.2 These findings support possible in-vivo prodrug conversion but do not establish human bioavailability, conversion fraction, clearance, plasma half-life, or clinical effect duration.2

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

CannabisLithiumStimulantsTramadol
Powered by TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
1P-ETH-LAD can produce tolerance very quickly after administration. This rapid buildup is typical of serotonergic psychedelics that act at the 5-HT2A receptor.3
Baseline Reset
Physiological tolerance typically returns to baseline after approximately 7 days of abstinence. Some users suggest that full restoration of the psychological or experiential aspects of the substance may require two weeks or longer between uses.
Half Tolerance
Approximately 3 days after ingestion, physiological tolerance is estimated to decrease to roughly half of its peak level.
Cross Tolerance

Serotonergic psychedelics, Tryptamines, Lysergamides

Harm Potential

Addiction & Dependence

Psychological

Extremely Low

1P-ETH-LAD is generally not regarded as habit forming, and repeated experiences may reduce the urge to take it again.citation needed As with many psychedelics, it is characterized more by self-limiting use than by reinforcement of continued use.

Psychosis Risk

Delusions are listed among possible cognitive effects during the experience. No quantified data exists on standalone psychosis risk.

History & Culture

1P-ETH-LAD emerged on the research chemical market in early 2016, with virtually no documented history of human usage prior to January of that year. The compound appeared alongside other novel lysergamide derivatives such as 1P-LSD and ETH-LAD, marketed primarily through online research chemical…

Legality

By Country

Illegal2
Turkey flagTurkeyIllegal
United Kingdom flagUnited KingdomIllegal (Psychoactive Substances Act)
Controlled / restricted2
Germany flagGermanyControlled (NpSG)
Switzerland flagSwitzerlandRestricted
Not scheduled1
United States flagUnited StatesUnscheduled (Federal Analogue Act applies)

References

Source Pages

  1. Bluelight: forum discussion – metallic taste & trip preparation (lysergamides)
  2. Drug Users Bible by Dominic Milton Trott
  3. Drug Users Bible: 1P-ETH-LAD
  4. Erowid: 1P-ETH-LAD Experience Vault
  5. Isomer Design (TiHKAL/PiHKAL)
  6. PsychonautWiki
  7. TiHKAL #12: ETH-LAD
  8. TripSit Factsheets
  9. Wikipedia

Citations

  1. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD). pmc.ncbi.nlm.nih.gov (n.d.). https://doi.org/10.1016/j.neuropharm.2019.1078561
  2. It is the 1- propionyl chemical derivative|derivative of ETH-LAD and is thought to act as a prodrug of ETH-LAD analogously to how 1P-LSD acts as a prodrug of LSD. (n.d.). https://doi.org/10.1002/dta.219612
  3. David E Nichols. (2016). Psychedelics. 68(2), 264-355. https://doi.org/10.1124/pr.115.0114781
  4. Anlage 1 NpSG (Stoffgruppen), Gruppe 5.2 Delta-9,10-Ergolene. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/anlage_1.html1
  5. Änderungen an Neue-psychoaktive-Stoffe-Gesetz (NpSG) – chronologische Übersicht. buzer.de (n.d.). https://www.buzer.de/gesetz/12250/l.htm1
  6. § 4 NpSG. (2019). https://www.gesetze-im-internet.de/npsg/__4.html12
  7. § 3 NpSG - Unerlaubter Umgang mit neuen psychoaktiven Stoffen. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__3.html1
  8. Swissmedic: Rohmaterialien und Erzeugnisse mit vermuteter betäubungsmittelähnlicher Wirkung (status 19.11.2024). swissmedic.ch (n.d.). https://www.swissmedic.ch/dam/swissmedic/it/dokumente/bewilligungen/btm/verzeichnis_der_rohmaterialienunderzeugnissemitvermuteterbetaeub.pdf.download.pdf/indice_des_matierespremieresetproduitsayantuneffetpresumesemblab.pdf1
  9. Cumhurbaşkanı Kararı: Karar Sayısı: 1335. (2019). https://resmigazete.gov.tr/eskiler/2019/07/20190720-19.pdf1
  10. Psychoactive Substances Act 2016. Legislation.gov.uk (n.d.). http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted123

Further Reading

  1. Halberstadt AL & Klein LM. Pharmacology of novel lysergamides
  2. Wagmann L et al. Serum hydrolysis of lysergamide prodrugs
  3. Wagmann L et al. Serum hydrolysis of lysergamide prodrugs including 1P-ETH-LAD

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Lyrea avatar
    Step 2 · First-pass review

    A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes8 human edits · latest

Times are UTCNewest first

24 July 2026

  1. Lyrea · Updated the article · also 1cP-AL-LAD, 1cP-LSD, 1cP-MiPLA

14 July 2026

  1. Lyrea · Updated the article

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the 1P-ETH-LAD article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.